SWKS
53
3
MAR
62
-3
MU
42
7
BK
66
-2
MLM
41
-2
PBI
59
-7
TXN
39
3
INTU
59
-3
FSLR
63
5
MRK
33
3
JPM
59
-3
CCI
23
-2
ORCL
52
-7
YUM
47
-2
DRI
48
3
PNC
53
-2
NWSA
73
-2
EFX
60
11
DIS
72
-5
ADM
30
-3
SWKS
53
3
MAR
62
-3
MU
42
7
BK
66
-2
MLM
41
-2
PBI
59
-7
TXN
39
3
INTU
59
-3
FSLR
63
5
MRK
33
3
JPM
59
-3
CCI
23
-2
ORCL
52
-7
YUM
47
-2
DRI
48
3
PNC
53
-2
NWSA
73
-2
EFX
60
11
DIS
72
-5
ADM
30
-3
Financhill
Back

Pacira BioSciences 10K Form

Sell
47

PCRX
Pacira BioSciences

Last Price:
19.89
Seasonality Move:
12.01%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive PCRX News And Ratings

See the #1 stock for the next 7 days that we like better than PCRX

PCRX Financial Statistics

Sales & Book Value

Annual Sales: $674.98M
Cash Flow: $49.83M
Price / Cash Flow: 5.57
Annual Sales: $16.24
Price / Book: 1.22

Profitability

EPS (TTM): -2.01000
Net Income (TTM): $-90.73M
Gross Margin: $490.31M
Return on Equity: -10.74%
Return on Assets: -5.77%

Pacira BioSciences Earnings Forecast

Key Pacira BioSciences Financial Ratios

  • The Gross Profit Margin over the past 16 years for PCRX is 72.64%.
  • The Selling, General & Administrative Expenses for PCRX have been equal to 39.92% of Gross Profit Margin.
  • The Research & Development expenses have been 11.30% of Revenue.
  • The Interest Expense is 41.26% of Operating Income.
  • The Net Earning history of PCRX is 6.22% of Total Revenues.
  • Per Share Earnings over the last 16 years have been positive in 8 years.

Pacira BioSciences Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: PCRX
CUSIP: 695127
Website: pacira.com

Debt

Debt-to-Equity Ratio: 0.78
Current Ratio: 2.25
Quick Ratio: 1.81

Price-to-Earnings

Trailing P/E Ratio: 22.25
Forward P/E Ratio: 6.8

PCRX Technical Analysis vs Fundamental Analysis

Sell
47
Pacira BioSciences (PCRX) is a Sell

Is Pacira BioSciences a Buy or a Sell?